Oral manifestation associated with avelumab
Emerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient’s quality of life. Avelumab is a relatively recent immunotherapy drug that is u...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906023001383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553743724675072 |
|---|---|
| author | Kevin Chung Annu Singh Joseph M. Huryn Cherry L. Estilo |
| author_facet | Kevin Chung Annu Singh Joseph M. Huryn Cherry L. Estilo |
| author_sort | Kevin Chung |
| collection | DOAJ |
| description | Emerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient’s quality of life. Avelumab is a relatively recent immunotherapy drug that is used in the treatment of both renal and metastatic urothelial carcinomas. However, oral manifestation, to the best of our knowledge, has not been reported in the literature in association. The purpose of this case report is to describe an oral manifestation associated with avelumab, and subsequent management to obtain resolution of symptoms. |
| format | Article |
| id | doaj-art-65c13f0e87ae4742b44213013a734408 |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-65c13f0e87ae4742b44213013a7344082025-01-09T06:15:08ZengElsevierOral Oncology Reports2772-90602024-03-019100148Oral manifestation associated with avelumabKevin Chung0Annu Singh1Joseph M. Huryn2Cherry L. Estilo3Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USADental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 1006, USADental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USACorresponding author.; Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USAEmerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient’s quality of life. Avelumab is a relatively recent immunotherapy drug that is used in the treatment of both renal and metastatic urothelial carcinomas. However, oral manifestation, to the best of our knowledge, has not been reported in the literature in association. The purpose of this case report is to describe an oral manifestation associated with avelumab, and subsequent management to obtain resolution of symptoms.http://www.sciencedirect.com/science/article/pii/S2772906023001383AvelumabMucositisImmune checkpoint inhibitorsOral adverse events |
| spellingShingle | Kevin Chung Annu Singh Joseph M. Huryn Cherry L. Estilo Oral manifestation associated with avelumab Oral Oncology Reports Avelumab Mucositis Immune checkpoint inhibitors Oral adverse events |
| title | Oral manifestation associated with avelumab |
| title_full | Oral manifestation associated with avelumab |
| title_fullStr | Oral manifestation associated with avelumab |
| title_full_unstemmed | Oral manifestation associated with avelumab |
| title_short | Oral manifestation associated with avelumab |
| title_sort | oral manifestation associated with avelumab |
| topic | Avelumab Mucositis Immune checkpoint inhibitors Oral adverse events |
| url | http://www.sciencedirect.com/science/article/pii/S2772906023001383 |
| work_keys_str_mv | AT kevinchung oralmanifestationassociatedwithavelumab AT annusingh oralmanifestationassociatedwithavelumab AT josephmhuryn oralmanifestationassociatedwithavelumab AT cherrylestilo oralmanifestationassociatedwithavelumab |